Compare Cytokinetics Inc (CYTK) vs F5 Inc (FFIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs F5 Inc — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while F5 Inc trades at $460.99 (market cap $26.14B). The key difference: F5 Inc is far larger — about 3× Cytokinetics Inc's market cap, and F5 Inc is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and F5 Inc for 38 Days on average.
| CYTK | FFIV | |
|---|---|---|
Market Cap | $8.62B | $26.14B |
Volume | 2,594,626 | 503,146 |
Sector | Health | Technology |
52-Week High | $87.26 | $469.79 |
52-Week Low | $54.76 | $223.99 |
Typical Hold Time | 19 Days | 38 Days |
Enterprise Value | $8.72B | $24.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
F5 (FFIV) trades at $466.65, down 0.67% on the day, with strong technical momentum showing a bullish moving average signal despite overbought RSI readings. The company demonstrates robust fundamentals with revenue growth from $2.7B in 2022 to $3.1B in 2025 and expanding net margins reaching 22.42%. Recent recognition as a leader in IDC MarketScape for WAAP platforms and AI security innovations highlight competitive positioning.
FFIV presents a mixed outlook with strong earnings beats and profitability offset by premium valuations (P/E 36.78). Analyst consensus leans cautious with 41% buy ratings and $416.60 price target below current levels. Key risks include competitive pressures in application security and potential valuation compression if growth moderates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →
